

References

This is the reference list to the ACE Clinical Guideline “Management of mild and moderate dementia in older adults”.

1. Subramaniam M, Abidin E, Asharani P, et al. Prevalence of dementia in Singapore: Changes across a decade. *Alzheimers Dement*. 2025;21(2):e14485.
2. Ramakrishnan C, Malhotra C. Challenges to accessing community dementia care services: a qualitative study. *BMC Health Serv Res*. 2025;25(1):747.
3. Lau JH, Abidin E, Jeyagurunathan A, et al. The association between caregiver burden, distress, psychiatric morbidity and healthcare utilization among persons with dementia in Singapore. *BMC Geriatr*. 2021;21(1):67.
4. Peng D, Shi Z, Xu J, et al. Demographic and clinical characteristics related to cognitive decline in Alzheimer disease in China: A multicenter survey from 2011 to 2014. *Medicine (Baltimore)*. 2016;95(26):e3727.
5. Steinberg M, Shao H, Zandi P, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. *Int J Geriatr Psychiatry*. 2008;23(2):170–177.
6. Reisberg B. Functional assessment staging (FAST). *Psychopharmacol Bull*. 1988;24(4):653–659.
7. Reisberg B, Ferris SH, de Leon MJ, et al. The Global Deterioration Scale for assessment of primary degenerative dementia. *Am J Psychiatry*. 1982;139(9):1136–1139.
8. Ministry of Health Malaysia. Management of Dementia 2021. 3rd ed. Ministry of Health Malaysia; 2021.
9. Bentvelzen A, Aerts L, Seeher K, et al. A comprehensive review of the quality and feasibility of dementia assessment measures: The Dementia Outcomes Measurement Suite. *J Am Med Dir Assoc*. 2017;18(10):826–837.
10. Morris JC. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. *Int Psychogeriatr*. 1997;9(Suppl 1):173–176.
11. Kjeldsen EW, Frikke-Schmidt R. Causal cardiovascular risk factors for dementia: insights from observational and genetic studies. *Cardiovasc Res*. 2024.
12. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. *Lancet*. 2024;404(10452):572–628.
13. Verdelho A, Pereira MG. Management of vascular risk factors in dementia. In: Frederiksen KS, Waldemar G, editors. Management of Patients with Dementia: The Role of the Physician. Springer International Publishing; 2021. p. 155–178.
14. Ross SD, Ziegert N, Rodriguez FS. Implementation of non-pharmacological interventions in dementia care: family caregiver perspective. *Home Health Care Manag Pract*. 2024;36(1):20–30.
15. Luxton D, Thorpe N, Crane E, et al. Systematic review of the efficacy of pharmacological and non-pharmacological interventions for improving quality of life of people with dementia. *Br J Psychiatry*. 2025:1–13.
16. Vu HT, Nguyen HT, Nguyen AT. Effectiveness of non-pharmacological interventions for dementia among the elderly: a randomized controlled trial. *Geriatrics (Basel)*. 2024;9(2).
17. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. *Lancet*. 2015;385(9984):2255–2263.
18. Liu C, Gao S, Li S. The effect of physical exercise intervention on the ability of daily living in patients with Alzheimer's dementia: a meta-analysis. *Front Aging Neurosci*. 2024;16:1391611.
19. Woods B, Rai HK, Elliott E, Aguirre E, Orrell M, Spector A. Cognitive stimulation to improve cognitive functioning in people with dementia. *Cochrane Database Syst Rev*. 2023;1(1):CD005562.
20. Soons LM, Deckers K, Tange H, et al. Associations of hearing and visual loss with cognitive decline and dementia risk: a 25-year follow-up of the Maastricht Aging Study. *Age Ageing*. 2024;53(12).

21. Samelli AG, Gonçalves NG, Padilha F, et al. Hearing loss and cognitive decline in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) during eight years of follow-up. *J Alzheimers Dis.* 2025;104(1):283–293.
22. Jiang F, Dong Q, Wu S, et al. A comprehensive evaluation on the associations between hearing and vision impairments and risk of all-cause and cause-specific dementia: results from cohort study, meta-analysis and Mendelian randomization study. *BMC Med.* 2024;22(1):518.
23. Desai R, Leung WG, Fearn C, et al. Effectiveness of Cognitive Stimulation Therapy (CST) for mild to moderate dementia: a systematic literature review and meta-analysis of randomised control trials using the original CST protocol. *Ageing Res Rev.* 2024;97:102312.
24. Chen X. Effectiveness of cognitive stimulation therapy (CST) on cognition, quality of life and neuropsychiatric symptoms for patients living with dementia: a meta-analysis. *Geriatr Nurs.* 2022;47:201–210.
25. Cao Y, Wang N, Zhang Q, et al. Effects of cognitive stimulation therapy on patients with dementia: an umbrella review of systematic reviews and meta-analyses. *Exp Gerontol.* 2023;177:112197.
26. Wang S, Li K, Peng X, et al. The efficacy of reminiscence therapy on the cognition of older patients with cognitive impairment or dementia: a meta-analysis based on regulatory factors. *Aging Clin Exp Res.* 2026;38(1):45.
27. Dai S, Yuan S, Zhang X, et al. Effect of physical activity on cognitive function of patients with Alzheimer's disease: a meta-analysis. *J Integr Neurosci.* 2026;25(1):42702.
28. Yang L, Yuan Z, Peng C. Effects of aerobic exercise on cognitive function and quality of life in patients with Alzheimer's disease: a systematic review and meta-analysis. *BMJ Open.* 2025;15(1):e090623.
29. Xiao Y, Fan Y, Feng Z. A meta-analysis of the efficacy of physical exercise interventions on activities of daily living in patients with Alzheimer's disease. *Front Public Health.* 2024;12:1485807.
30. Kudlicka A, Martyr A, Bahar-Fuchs A, et al. Cognitive rehabilitation for people with mild to moderate dementia. *Cochrane Database Syst Rev.* 2023;6(6):CD013388. doi:10.1002/14651858.CD013388.pub2.
31. Devita M, Masina F, Mapelli D, et al. Acetylcholinesterase inhibitors and cognitive stimulation, combined and alone, in treating individuals with mild Alzheimer's disease. *Aging Clin Exp Res.* 2021;33(11):3039–3045.
32. Veroniki AA, Ashoor HM, Rios P, et al. Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis. *BMJ Open.* 2022;12(4):e053012.
33. National Institute for Health and Care Excellence. (2018) Dementia: assessment, management and support for people living with dementia and their carers (NG97). [Accessed June 2025] <https://www.nice.org.uk/guidance/ng97>.
34. Chen Y, Lai M, Tao M. Evaluating the efficacy and safety of Alzheimer's disease drugs: a meta-analysis and systematic review. *Medicine (Baltimore).* 2024;103(16):e37799.
35. Zuliani G, Zuin M, Romagnoli T, et al. Acetyl-cholinesterase-inhibitors reconsidered. A narrative review of post-marketing studies on Alzheimer's disease. *Aging Clin Exp Res.* 2024;36(1):23.
36. Zuin M, Cherubini A, Volpato S, et al. Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with dementia. *Sci Rep.* 2022;12(1):12214.
37. McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. *Cochrane Database Syst Rev.* 2019;3(3):CD003154.
38. Yaghmaei E, Lu H, Ehwerhemuepha L, et al. Combined use of donepezil and memantine increases the probability of five-year survival of Alzheimer's disease patients. *Commun Med (Lond).* 2024;4(1):99.
39. Havreng-Théry C, Oquendo B, Zolnowski-Kolp V, et al. Cholinesterase inhibitors and memantine are associated with a reduced mortality in nursing home residents with dementia: a longitudinal observational study. *Alzheimers Res Ther.* 2024;16(1):117.
40. Sheikh M, Ammar M. Efficacy of 5 and 10 mg donepezil in improving cognitive function in patients with dementia: a systematic review and meta-analysis. *Front Neurosci.* 2024;18.

41. Tang-Wai DF, Smith EE, Bruneau MA, et al. CCCDTD5 recommendations on early and timely assessment of neurocognitive disorders using cognitive, behavioral, and functional scales. *Alzheimers Dement*. 2020;6(1):e12057.
42. Battle CE, Abdul-Rahim AH, Shenkin SD, et al. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. *Cochrane Database Syst Rev*. 2021;2(2):CD013306.
43. Reeve E, Farrell B, Thompson W, et al. Evidence-Based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine. The University of Sydney; 2018.
44. Reeve E, Wiens J, Kuas M, et al. Deprescribing cholinesterase inhibitors and memantine in people with dementia: a systematic review. *J Am Geriatr Soc*. 2023;71(3):669–680.
45. Reeve E, Farrell B, Thompson W, et al. Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary. *Med J Aust*. 2019;210(4):174–179.
46. Ismail Z, Black SE, Camicioli R, et al. Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. *Alzheimers Dement*. 2020;16(8):1182–1195.
47. Cloak N, Schoo C, Al Khalili Y. (2025) Behavioral and psychological symptoms in dementia. In: StatPearls [Internet]. StatPearls Publishing. [Accessed June 2025] <https://www.ncbi.nlm.nih.gov/books/NBK551552/>.
48. McGowan B, Gibb M, Cullen K, et al. Non-Cognitive Symptoms of Dementia (NCSD): Guidance on Non-Pharmacological Interventions for Healthcare and Social Care Practitioners. National Dementia Office; 2019.
49. Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. *Front Neurol*. 2012;3:73.
50. Vaingankar JA, Chong SA, Abidin E, et al. Behavioral and psychological symptoms of dementia: prevalence, symptom groups and their correlates in community-based older adults with dementia in Singapore. *Int Psychogeriatr*. 2017;29(8):1363–1376.
51. BPAC NZ. (2020) Managing the behavioural and psychological symptoms of dementia. [Accessed June 2025] <https://bpac.org.nz/2020/bpsd.aspx>.
52. Kröger E, Moulis M, Wilchesky M, et al. Adverse drug reactions reported with cholinesterase inhibitors: an analysis of 16 years of individual case safety reports from VigiBase. *Ann Pharmacother*. 2015;49(11):1197–1206.
53. Jaqua EE, Nguyen VTN, Chin E. Delirium in older persons: prevention, evaluation, and management. *Am Fam Physician*. 2023;108(3):278–287.
54. Todd OM, Teale EA. Delirium: a guide for the general physician. *Clin Med (Lond)*. 2017;17(1):48–53.
55. Weidmann AE, Proppé GB, Matthíasdóttir R, et al. Medication-induced causes of delirium in patients with and without dementia: a systematic review of published neurology guidelines. *Int J Clin Pharm*. 2025;47(3):606–623.
56. van der Linde RM, Denning T, Stephan BC, Prina AM, Evans E, Brayne C. Longitudinal course of behavioural and psychological symptoms of dementia: systematic review. *Br J Psychiatry*. 2016;209(5):366–377.
57. Mendez MF. Managing the behavioural and psychological symptoms of dementia. *Curr Treat Options Neurol*. 2022;24(5):183–201.
58. Deardorff WJ, Grossberg GT. Behavioral and psychological symptoms in Alzheimer's dementia and vascular dementia. In: Reus VI, Lindqvist D, editors. *Handbook of Clinical Neurology*. Vol. 165. Elsevier; 2019. p. 5–32.
59. Vaci N, Koychev I, Kim C-H, et al. Real-world effectiveness, its predictors and onset of action of cholinesterase inhibitors and memantine in dementia: retrospective health record study. *Br J Psychiatry*. 2021;218(5):261–267.
60. Machado-Vieira R, Baumann J, Wheeler-Castillo C, et al. The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments. *Pharmaceuticals (Basel)*. 2010;3(1):19–41.
61. dos Santos Fernandes F, Pimentel FC, Carneiro AM, et al. Rapid response to antidepressants and correlation with response and remission after acute treatment. *J Affect Disord Rep*. 2024;16:100725.

62. Agid O, Kapur S, Arenovich T, et al. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. *Arch Gen Psychiatry*. 2003;60(12):1228–1235.
63. Meyer R, Skov K, Dhillon IK, et al. Onset of action of selected second-generation antipsychotics (Pines) – a systematic review and meta-analyses. *Biomedicines*. 2023;11(1):82.
64. Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. *J Clin Psychiatry*. 2008;69(3):341–348.
65. Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. *Int J Geriatr Psychiatry*. 2008;23(5):537–545.
66. Chen A, Copeli F, Metzger E, et al. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on management of behavioral and psychological symptoms in dementia. *Psychiatry Res*. 2021;295:113641.
67. Ireland Department of Health. (2019) Appropriate Prescribing of Psychotropic Medication for Non-Cognitive Symptoms in People with Dementia (NCEC National Clinical Guideline No. 21). [Accessed June 2025] <https://www.gov.ie/en/department-of-health/collections/appropriate-prescribing-of-psychotropic-medication-for-non-cognitive-symptoms-in-people-with-dementia/>
68. Bittner N, Funk CSM, Schmidt A, et al. Psychiatric adverse events of acetylcholinesterase inhibitors in Alzheimer's disease and Parkinson's dementia: systematic review and meta-analysis. *Drugs Aging*. 2023;40(11):953–964.
69. Chen K, Li H, Yang L, et al. Comparative efficacy and safety of antidepressant therapy for the agitation of dementia: a systematic review and network meta-analysis. *Front Aging Neurosci*. 2023;15:1103039.
70. Seitz DP, Adunuri N, Gill SS, et al. Antidepressants for agitation and psychosis in dementia. *Cochrane Database Syst Rev*. 2011;(2):CD008191.
71. Kongpakwattana K, Sawangjit R, Tawankanjanachot I, et al. Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta-analysis. *Br J Clin Pharmacol*. 2018;84(7):1445–1456.
72. Sultan S. Treating depression in dementia patients: a risk or remedy – a narrative review. *Geriatrics (Basel)*. 2024;9(3).
73. Banerjee S, Farina N, Henderson C, et al. A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trial. *Health Technol Assess*. 2023;27(23):1–108.
74. Rogowska M, Thornton M, Creese B, et al. Implications of adverse outcomes associated with antipsychotics in older patients with dementia: a 2011–2022 update. *Drugs Aging*. 2023;40(1):21–32.
75. DeMercy HM, Brenner CA. The relationship between antipsychotics, cognitive enhancers, and major adverse cardiovascular/cerebrovascular events (MACCE) in older adults with behavioral and psychological symptoms of dementia. *Drugs Aging*. 2024;41(10):847–858.
76. Cummings J, Sano M, Auer S, et al. Reduction and prevention of agitation in persons with neurocognitive disorders: an international psychogeriatric association consensus algorithm. *Int Psychogeriatr*. 2024;36(4):251–262.
77. Benjamin S, Ho JM-W, Tung J, et al. Anticonvulsants in the treatment of behavioral and psychological symptoms in dementia: a systematic review. *Am J Geriatr Psychiatry*. 2024;32(10):1259–1270.
78. Baillon SF, Narayana U, Luxenberg JS, et al. Valproate preparations for agitation in dementia. *Cochrane Database Syst Rev*. 2018;10(10):CD003945.
79. Lyon M, Fullerton J, Kennedy S, et al. Hypertension & dementia: pathophysiology & potential utility of antihypertensives in reducing disease burden. *Pharmacol Ther*. 2024;253:108575.
80. Ruangritchankul S, Chantharit P, Srisuma S, et al. Adverse drug reactions of acetylcholinesterase inhibitors in older people living with dementia: a comprehensive literature review. *Ther Clin Risk Manag*. 2021;17:927–949.